ABIONYX Pharma is a new generation biotech company dedicated to the discovery and development of innovative therapies for patients without existing or effective treatment.

Using current resources, ABIONYX plans to advance activities with existing development assets inherited from Cerenis. ABIONYX is also exploring joint activities with a number of attractive partners.

ABIONYX initiates a Phase 2a clinical trial with CER-001 in septic patients at high risk of developing Acute Kidney Injury

  • This partnered clinical study with the University of Bari and the CBVF foundation is already fully funded
  • Temporary Authorization for Named Use (ATUn) showed promising efficacy in renal diseases
  • Evaluation of the clinical activity by dosage level of CER-001 in the prevention of Acute Kidney Injury in ICU patients with septicemia
  • A potentially modifying effect on the progression of the inflammatory cascade in sepsis
  • Pending positive data, the company aims to move into Phase 2b by end of 2021

READ MORE

Contribute to the development of innovative therapies for patients without existing or effective treatment

ABIONYX Pharma is a new generation biotech company dedicated to the discovery and development of innovative therapies for patients without existing or effective treatment

The biotech assets inherited from CERENIS Therapeutics constitute a rich portfolio of valuable programs for the treatment of cardiovascular diseases and associated metabolic diseases such as NAFLD and NASH as well as a HDL targeted drug delivery platform in oncology , more specifically in immuno oncology and chemotherapy